Stock BSPM BIOSTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biostar Pharmaceuticals, Inc.

Equities

BSPM

US0906783016

Delayed OTC Markets
Other stock markets
 12:22:33 31/05/2024 am IST 		5-day change 1st Jan Change
0.000014 USD -86.00% Intraday chart for Biostar Pharmaceuticals, Inc. -.--% -86.00%
2023 Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer CI
2023 Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule
CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.
CI
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index
CI
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals
CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.
CI
Biostar Pharmaceuticals, Inc. Announces Board Changes
CI
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee
CI
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director
CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
CI
Biostar Pharmaceuticals Seeks Acquisitions
CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.
CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017
CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016
CI
Biostar Pharmaceuticals, Inc. Announces Management Changes
CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
CI
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis
CI
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.
CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BSPM Stock
  4. News Biostar Pharmaceuticals, Inc.